@1wendy27's testosterone pellet rant, fact-checked

What did @1wendy27 actually say?

She laid out her personal side effect experience after her first testosterone pellet insertion: chin hair growth, mild hair shedding, lower abdominal bloating that resolved in a few weeks, and a significant jump in libido. She also reported clear benefits, including disappearance of night sweats, lifted brain fog, better energy, and improved gym performance. She attributed the bloating to "water retention due to your hormones optimizing" and said she pre-loaded with biotin, zinc, and saw palmetto to blunt hair shedding. Nothing in this video is medically reckless. It reads as an honest personal account, not a sales pitch dressed up as testimony.

Does the science back this up?

Mostly, yes. The side effects she described are consistent with what the clinical literature documents for testosterone therapy in women, though the pellet-specific evidence base is thinner than many providers admit.

Androgenic effects like facial hair and hair shedding (androgenic alopecia) are well-documented with supraphysiologic testosterone exposure. A 2019 review by Islam et al. in Clinical Endocrinology noted androgenic side effects occur in 20-30% of women on testosterone therapy, with the risk scaling to dose. Pellets are notoriously difficult to dose precisely because they cannot be removed once inserted, which makes androgenic side effects harder to reverse if they occur.

The libido increase she describes is supported by a reasonable body of evidence. A 2019 Lancet Diabetes and Endocrinology international consensus position statement by Davis et al. found testosterone therapy in women improved sexual function, including desire, arousal, and satisfaction, based on randomized controlled trial data. That part checks out.

Her claim that bloating is "water retention due to hormones optimizing" is plausible but oversimplified. Testosterone can convert to estradiol via aromatization, and estrogen is a well-known driver of fluid retention. Whether this constitutes "optimization" or just a hormonal adjustment period is a framing choice, not a clinical fact.

What did they get wrong (or right)?

The biotin-zinc-saw palmetto pre-loading strategy she mentions deserves scrutiny. She presents it as received wisdom from a support group, and it has some logic behind it, but the evidence is not strong. Biotin for hair retention has very limited clinical support in otherwise healthy individuals. Saw palmetto has modest data for androgenic alopecia in men (Wessagowit et al., 2016, Journal of Dermatological Treatment), but female-specific data is sparse. Zinc's role is similarly indirect. None of this is harmful, but presenting it as a reliable prophylactic strategy is optimistic.

What she got right: she acknowledged real side effects exist, she tracked her labs, and she didn't claim pellets are universally safe or effective. That's a more responsible framing than a lot of what circulates in the BioTE-adjacent social media space. Her point that she monitors symptoms and calls for labs when she feels her levels dropping reflects a reasonable, patient-engaged approach to hormone management.

What the video does not address: pellet dosing is irreversible mid-cycle. If her androgens had run too high, she could not have simply stopped treatment. That is a meaningful clinical limitation that gets glossed over in most pellet advocacy content.

What should you actually know?

Testosterone therapy for women is not FDA-approved in the United States, though it is used off-label extensively. The evidence for symptom relief, particularly for low libido and energy, is real but concentrated in specific populations, mostly postmenopausal women. The Davis et al. 2019 consensus statement is the most authoritative current summary and it supports use for hypoactive sexual desire disorder specifically, not general "optimization."

Pellets as a delivery method carry a specific risk profile. Because they release testosterone continuously and cannot be adjusted after insertion, overdosing is a genuine concern. A 2020 study by Glaser and Dimitrakakis in Maturitas reported benefits in their pellet patient cohort, but critics note the lack of randomized controlled trial data for pellets specifically and the financial conflicts common in that research stream.

The BioTE brand, which she hashtags extensively, is a franchise model that trains providers and sells proprietary pellets. This is not inherently disqualifying, but patients should know they are operating within a commercially structured ecosystem, not a neutral medical one. Ask your provider about their financial relationship with any pellet brand before signing on.

Bottom line: her side effect list is credible and her overall approach, labs first, monitor symptoms, acknowledge tradeoffs, is more responsible than average. But the irreversibility of pellets and the absence of FDA approval for this indication are facts that did not make it into this video, and they matter.